Canadian company Aurora Cannabis has signed a five-year agreement with MedReleaf to act as the exclusive supplier in Australia of Aurora’s MedReleaf, CanniMed and Aurora brands.
Products covered by the agreement will be EU-GMP certified and include dried flower, oils and soft gels, as well as future products employing new delivery mechanisms. The agreement does not require or include any capital investment by Aurora, which already holds a 10% stake in MedReleaf.
Aurora CEO Miguel Martin said: “The team at MedReleaf have created an asset-light, sustainable growth platform in Australia to assist physicians, pharmacists and patients across the country in accessing the high-quality range of Aurora cannabis medicines.”
MedReleaf CEO Russell Harding added: “Australia’s medical cannabis system is well designed, well regulated and among the fastest growing in the world.
“Our strategic supply agreement with Aurora ensures that our patients will have reliable access to cannabis medicines with a worldwide reputation for quality and in accordance with the stringent requirements of [the] Therapeutic Goods Administration.”